What smart money is saying about Virbac
VIRP.PA
No fund has written a full thesis on Virbac in our archive, but 2 fund letters report a position in it, most recently Glendale Equity in September 2026.
Get an email when a fund buys, sells or pitches it
2
Reported positions
2
Bought
0
Sold
2
Letters
Position history
Between Q2 2026 and Q3 2026, 2 fund letters reported a position in Virbac, with 2 buys (opened or added).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 1 | 0 | 0 |
| Q2 2026 | 1 | 1 | 0 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 2 positions · 2 moves
- AddedGlendale EquitySeptember 2026
“We also made additional purchases of Inditex, Ryanair and Virbac during the month of September.”
Virbac - New positionDNCA Invest Explorer Smid EuroJune 2026
“Finally, we initiated a line in Virbac, an animal health company, whose growth profile and management change seem attractive to us.”
Virbac
Read the letters behind these Virbac positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves, and to Warren AI, which reads all of them for you.
View plans→Share this ledger